Dosoky Noura S, Guo Lilu, Chen Zhongyi, Feigley Andrew V, Davies Sean S
Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University , Rm 556 Robinson Research Building, 2200 Pierce Avenue, Nashville, Tennessee 37232-6602, United States.
ACS Infect Dis. 2018 Jan 12;4(1):3-13. doi: 10.1021/acsinfecdis.7b00127. Epub 2017 Oct 17.
Engineering the gut microbiota to produce specific beneficial metabolites represents an important new potential strategy for treating chronic diseases. Our previous studies with bacteria engineered to produce N-acyl-phosphatidylethanolamines (NAPEs), the immediate precursors of the lipid satiety factors N-acyl-ethanolamides (NAEs), found that colonization of these bacteria inhibited development of obesity in C57BL/6J mice fed a high fat diet. Individual NAE species differ in their bioactivities. Intriguingly, colonization by our engineered bacteria resulted in increased hepatic N-stearoyl-ethanolamide (C18:0NAE) levels despite the apparent inability of these bacteria to biosynthesize its precursor N-stearoyl-phosphatidylethanolamine (C18:0NAPE) in vitro. We therefore sought to identify the factors that allowed C18:0NAPE biosynthesis by the engineered bacteria after colonization of the intestinal tract. We found that the species of NAPE biosynthesized by engineered bacteria depends on the species of dietary fatty acids available in the intestine, suggesting a simple method to fine-tune the therapeutic effects of modified microbiota.
改造肠道微生物群以产生特定的有益代谢物是治疗慢性疾病的一种重要的新潜在策略。我们之前对经过工程改造以产生N-酰基磷脂酰乙醇胺(NAPEs)的细菌进行的研究发现,这些细菌的定殖抑制了喂食高脂肪饮食的C57BL/6J小鼠肥胖症的发展,N-酰基磷脂酰乙醇胺是脂质饱腹感因子N-酰基乙醇胺(NAEs)的直接前体。不同的NAE种类具有不同的生物活性。有趣的是,尽管这些细菌在体外明显无法生物合成其前体N-硬脂酰磷脂酰乙醇胺(C18:0NAPE),但经我们改造的细菌定殖后,肝脏中N-硬脂酰乙醇胺(C18:0NAE)的水平却有所升高。因此,我们试图确定肠道定殖后使改造后的细菌能够进行C18:0NAPE生物合成的因素。我们发现,改造后的细菌生物合成的NAPE种类取决于肠道中可获得的膳食脂肪酸种类,这提示了一种微调改造后微生物群治疗效果的简单方法。